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Background: The anaplastic lymphoma kinase (ALK) inhibitor 
crizotinib has recently received approval for the treatment of patients 
with locally advanced or metastatic ALK-positive non–small-cell 
lung cancer (NSCLC). As the therapeutic prescription postulates the 
detection of ALK rearrangements, reliable diagnostic approaches 
are of utmost importance. With this study, we present the data of 
the first German ALK-round robin test based on genomic DNA in 
situ hybridization (ISH). The application of immunohistochemistry 
(IHC) for ALK protein detection was optional and not required for 
certification.
Methods: Two tissue microarrays, each consisting of the same 10 
NSCLC but in different arrangement of the cases, were generated 
(five unequivocally ALK-positive and five unequivocally ALK-
negative cases). ISH-based results and optional IHC data had to be 
submitted within 10 working days. A successful participation (cer-
tification) was reached if at least 19 of the 20 possible points were 
scored (2 points for a correct case classification).
Results: Fifty-three of 59 participants (89.8%) provided their 
data for ISH-ALK detection within the submission period. 
Thirty-two of 53 participants (60.3%) received at least 19 points 
required for certification. Remarkably, the range of cells with 
aberrant ALK signal configuration was broad in ALK-negative 
(0–13%) and in ALK-positive cases (15–95%). Thirty-five par-
ticipants supported the round robin test with optional ALK IHC 
results, which displayed a great heterogeneity in the ALK ISH-
positive cases.
Conclusion: In essence, our ALK ISH round robin test clearly dem-
onstrates that there is accumulating need for improvement of ALK 
testing. Although ISH may be regarded as a well-established pro-
cedure, its broad application in a diagnostic setting is challenging 
and requires standardized methods and harmonized interpretation to 
achieve sound results for therapeutic decisions. The same is true for 
ALK IHC which, however if standardized, might improve the diag-
nostic approach.
Key Words: Non–small-cell lung cancer, Anaplastic lymphoma 
kinase gene rearrangement, Fluorescence in situ hybridization, 
Immunohistochemistry, Round robin test.
(J Thorac Oncol. 2014;9: 1464–1469)
Lung cancer still remains the leading cause of death by cancer worldwide.1–3 In 2007, a rare but therapeutically targetable 
mutation has been described by Soda et al.,4 which affects a 
genomic break in the gene of the anaplastic lymphoma kinase 
(ALK): a small paracentric inversion within the short arm of 
chromosome two mostly leads to an open reading frame that links 
the first exons of EML4 to the 3′ part of ALK.4 This genomic 
event leads to the generation of the EML4-ALK fusion gene and, 
as consequence, to an activation of the ALK-kinase. Crizotinib, 
an orally dispensable ALK inhibitor, has received approval by 
the Food and Drug Administration (FDA) in August 2011 and by 
the European Medicines Agency (EMA) in October 2012 for the 
treatment of patients with locally advanced or metastatic ALK-
positive non–small-cell lung cancer (NSCLC). Thus, a new ther-
apeutic concept was born.5–7 However, as only 2% to 7% of the 
NSCLC patients carry this alteration,5–7 an adequate and reliable 
testing has to be performed to exactly detect these patients.8–10 To 
identify institutions capable of providing high-quality molecu-
lar testing, the QuiP initiative (“Qualitätssicherungs-Initiative 
Pathologie” or “Quality in Pathology”) organizes quality control 
(QC) rounds (round robin tests) for respective diagnostic appli-
cations in Germany.
Here, we present the data of the first ALK-round robin 
test (for Germany, Austria, and Switzerland), which was 
based on the experiences of a preceding expert panel test.11 
As the studies leading to crizotinib approval performed ALK 
detection by means of fluorescence in situ hybridization 
(FISH)5,6,12–14 and the data derived from the pretesting phase 
revealed very inhomogeneous results for ALK immunohisto-
chemistry (IHC),11 genomic in situ hybridization (ISH), per-
formed by the participating pathologists, provided the basis 
for certification of this first QuiP ALK quality round.
MATERIALS AND METHODS
Case Selection by an Expert 
Panel and Prescreening
In preparation for this ALK-round robin test, an expert 
panel of eight institutes of pathology experienced in ALK 
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detection performed a preceding internal panel testing of 10 
NSCLC cases by means of IHC and FISH.11,15 As a result, 
five unequivocally ALK-break negative and five unequivo-
cally ALK-break positive NSCLC cases were chosen to 
be appropriate for the ALK-round robin test. The samples 
had been additionally tested by RT-PCR.11,15 Whole tissue 
slide reevaluation of theses cases revealed ALK split sig-
nals not exceeding 3% of 100 evaluated tumor cells in all 
five ALK-break negative samples and unequivocally ALK 
alterations in 41% to 73% of 100 evaluated tumor cells in 
all five ALK-break positive samples. Three of the five ALK-
break positive cases showed essentially ALK split signals 
(SS), mainly one per nucleus. The remaining two harbored 
essentially ALK-single red signal (SRS), mainly one per 
nucleus (Fig. 1).
Tissue Microarray-Construction and Retesting
Two tissue microarrays (TMA), each consisting of the 
same pretested 10 NSCLC cases, were designed differing 
in the alignment of the cases. From each case, three cores 
(diameter per core: 1 mm), harboring representative regions 
of the tumor, were generated resulting in two TMAs each 
with a total of 30 cores. Furthermore, two landmark cores 
(palatine tonsils) serving as orientation and as negative con-
trol were additionally placed in the right upper corner of 
each TMA. One hundred serial sections (3–5 µm each) were 
cut from each TMA. Sections 1, 50, and 99 were stained 
by H&E; sections 2, 51, and 100 of each TMA were inde-
pendently retested by FISH in Berlin and Heidelberg and 
confirmed the pretested ALK status. The number (%) of 
ALK-altered tumor cells was comparable within the differ-
ent TMA-levels and confirmed the split-percentages of the 
prescreening (see below).
FISH of Whole Slide Tissue Sections and TMAs
Three- to five-μm thick sections were cut, mounted on 
SuperFrost +/+ slides and deparaffinized. A commercially 
available break-apart dual color probe for the ALK gene 
(Vysis LSI ALK Dual Color; Abbott Molecular, Abbott Park, 
IL) was used in accordance to the manufacturer’s instructions. 
The 5′ ALK probe was labeled with SpectrumGreen and the 
3′ ALK probe with SpectrumOrange. One hundred nonover-
lapping cells with hybridization signals (prescreening and 
reevaluation of whole slide tissue sections) and accordingly 
50 nonoverlapping cells with hybridization signals (TMA-
based retesting) were examined for each case with a fluores-
cence microscope (Axio Imager Z1, Zeiss) at a 63× objective 
(oil immersion objective), recording a detailed signal pattern 
for each cell. ALK FISH was considered positive if at least 
15% of the tumor cells showed splitting (SS) of the fluores-
cent probes flanking the ALK gene or isolated 3′ (red) signals 
(SRS), as described elsewhere.10–20 Cells lacking any hybrid-
ization signal were not evaluated. The ALK status of each 
single case was the same within the whole slide tissue sec-
tions and at the different levels of both TMA-sections. There 
were no noteworthy differences concerning the percentage of 
the ALK-positive and -negative tumor cells between the whole 
slide tissue sections and the different TMA-sections.
Round Robin Test and Certification
TMA-slides were shipped to the participants of the 
ALK-round robin within four weeks of being cut. Each of the 
59 participants received three slides. Each laboratory had to 
perform ISH testing (Fluorescence-ISH and/or Chromogenic 
ISH as basis for certification), whereas IHC testing was 
demanded as add-on method only (thus not a basis for certifi-
cation). Concerning the latter, the participants were asked to 
FIGURE 1.  Demonstration of all 
10 cases of the round robin test  
(H&E staining with objective ×10–×40 
and FISH-image with ×63  objective). 
Besides the FISH-signal pattern within 
each case, the success rate of all 
53 participants is illustrated.
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provide information of the clone, the dilution and the detec-
tion system as detailed as possible (facultative information). 
ALK IHC-staining intensity should be scored as 0, 1, 2, or 
3. Furthermore the percentage of positive stained tumor cells 
was requested. H&E slides of the two TMAs were electroni-
cally available as digital slides (Nanozoomer 2.0; Hamamatsu) 
at different levels (slides 1, 50, and 99) for online review by 
all participating institutes. The participating pathologists had 
been requested to submit their results within 10 working days 
as a combined consideration of all three cores per case.
As a conclusion of the daily routine practice and the inter-
nal ALK-round robin test11,15 the expert panel stated that cases 
with clear ALK breaks (split signal distances ≥2) might also dis-
play some ALK-break positive cells with split signal distances 
around 1.5 and 2 (“subtle splits”). These considerations reflect 
spatial aspects as the ALK split in the 2-dimensional plane can-
not always fully reflect the 3-dimensional split distance and is 
highly dependant on the angle of how the cell is being cut.21 
Thus the two FISH probe signals might appear much closer 
in 2-D than they actually are in 3-D. This might explain false-
positive and negative FISH interpretations.11,12,21,22 Furthermore, 
an exact split distance measurement is a matter of subjectivity 
and is influenced by the circumstance that some observers per-
form ALK FISH by microscope only, whereas others refer to 
digital support (e.g., the computed-based ISIS Multicolor FISH 
[mFISH] application by MetaSystems). These potentially prob-
lematic issues especially within a TMA-based multicenter test-
ing were considered in the definition of ALK-break positivity 
within the guidelines of this round robin. All participants had 
been informed as follows: “The well-known and published split 
signal definition of greater than or equal to 2 is a criterion that 
does not fit for all ALK-rearranged cells in ALK-positive sam-
ples. Even though the split distance in unequivocally ALK-break 
positive samples lays in this given definition in the majority of the 
tumor cells, some ALK-break positive tumor cells might show 
splits with distances between approximately 1.5 and 2 diameters 
only. Therefore, the round robin definition for ALK-break posi-
tivity was defined as (1) a distance of significantly more than one 
signal diameter between the 5′ (green) and 3′ (red) signal in (2) 
at least 15% of the evaluated tumor cells.”
Scoring System for ALK Certification
For correct assessment of the ALK status two points 
were given whereas no point was provided for an incorrect 
evaluation. ALK FISH is technically challenging and can be 
complicated by certain tissue characters as necrosis, fibro-
sis, high amount of bronchus tissue or low amount of tumor 
cells. These aspects might even become more problematic in a 
multicenter TMA-based testing as, depending on the level of 
the TMA-section, an unequivocal ALK interpretation might 
be more difficult in one part of the TMA than in another part. 
In the routine diagnostics these circumstances would lead 
to a retesting. This is not possible in extenso in a QC (only 
three slides were shipped to all participants for ISH and IHC). 
Therefore the participants had the opportunity to state maxi-
mal one case as “not evaluable,” which means under real diag-
nostic conditions they would retest. At least 19 of 20 maximal 
points were required for successful participation, as theoreti-
cally with 19 points the observer did not perform a (mis) diag-
nosis that would have led to a wrong therapy prescription.
RESULTS
Number of Participating Institutes
Fifty-nine institutes (53x Germany, 4x Austria, 2x 
Switzerland) registered for the round robin test. 53 (89.8%) 
submitted their results within the given deadline. Six partic-
ipants (10.2%) missed the deadline or stated that their ISH 
did not produce any interpretable results due to laboratory-
based reasons (e.g., autofluorescence and overdigestion with 
no evaluable signals) and where therefore excluded form the 
overall analyses.
Total Performance of the 
Participating Institutes
Thirty-two of 53 (60.3%) participants (26x Germany, 4x 
Austria, 2x Switzerland) achieved 20 of 20 (18 participants) 
or 19 of 20 (14 participants) points and thus accomplished 
the round robin test successfully. The remaining 21 partici-
pants had 18 points or less ranging from 18 to 8 points (mean 
value within these 21 participants: 15.0 points) and thus failed 
a successful participation. The mean value within all 53 par-
ticipants was 17.7 points. All 53 participants evaluated a total 
of 1515 of 1590 (95.3%) possible TMA cores (53 participants 
× 10 cases × 3 cores per case). The difference in the number of 
evaluated cores between the successful (96.3%) and the fail-
ing participants (93.8%) was negligible (Table 1).
Methods Used for ALK-Break Detection
Ten participants (18.9%) submitted no detailed technical 
information regarding the method used for ALK detection. The 
remaining 43 participants applied FISH (n = 41) or chromogenic 
ISH (CISH) (n = 2; both Zytovision, one participant reached 
20 points, the other 19). 22 of the 41 participants (53.7%) per-
formed FISH by using the Zytovision probe whereas 17 (41.5%) 
employed the probe provided by Abbott. One participant used the 
TABLE 1.  Total Performance of the 53 Participating Institutes
Points 20 19 18 17 16 15 13 12 8 Mean value
Number of participants 18 14 2 2 6 6 1 2 2 17.7 points
Evaluated TMA cores 924/960 (96.3%) 591/630 (93.8%) 1515/1590 (95.3%)
Thirty-two of 53 (60.3%) participants achieved 20 of 20 (18 participants) or 19 of 20 (14 participants) points and thus accomplished the round robin test successfully. The remaining 
21 participants had 18 points or less ranging from 18 to 8 points (mean value within these 21 participants: 15.0 points). The mean value within all 53 participants was 17.7 points. All 
53 participants evaluated a total of 1515 of 1590 possible TMA cores (95.3%). The number of evaluated cores between the successful (96.3%) and the failing participants (93.8%) was 
negligible.
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latter two probes simultaneously and one participant employed 
the probe of Kreatech. There was no bias regarding successful 
participation by using a certain FISH or CISH probe.
Results of the In Situ Hybridization (FISH, CISH)
A detailed description of all cases and the results 
of FISH/CISH provided by the participant are depicted in 
Tables 2 and 3. Whereas most of the cases without ALK breaks 
revealed a correct classification by the participants, misinter-
pretation of the ALK-break positive cases was the main reason 
for missing the required 19 points for successful participation. 
Remarkably, there was a broad range of interpretation, regard-
ing the number of ALK-break positive cells within single 
cases among the participants (0–13% in ALK-break negative 
and 15–95% in ALK-break positive cases).
Results of the Optional ALK IHC
IHC was performed by a total of 35 of 53 participants 
(66%). Commercially available ALK IHC antibodies were 
used as follows: 11x Dako (clone ALK-1), 6x Ventana (clone 
ALK-1), 5x Cell-Signaling (clone D5F3), 4x Novocastra 
(clone 5A4), 2x Ventana (clone D5F3), 1x Abcam (clone 
5A4), 1x Zeta Corporation (clone SP8), five participants did 
not provide their antibody data, four of them further did not 
provide any data on dilution and detection systems. The detec-
tion rates by IHC of the five ALK-break positive samples var-
ied and the success rates were relatively low (case 3: 22 of 
35 [62.9%], case 5: 3 of 35 [8.6%], case 7: 14 of 35 [40%], 
case 8: 20 of 35 [57.7%], case 10: 2 of 35 [5.7%]). Two of 35 
(5.7%) participants would have detected all five ALK FISH-
positive cases by means of IHC (utilized antibodies: Ventana/
clone D5F3 and Novocastra/clone 5A4). For further informa-
tion see Supplemental Table (Supplemental Digital Content, 
http://links.lww.com/JTO/A672).
DISCUSSION
We describe the outcome of the first multicenter ALK 
testing of 10 NSCLC samples in Germany, Austria, and 
Switzerland. Sixty percent of the observers participated 
successfully in this ISH-based round robin test. However, 
even if the ALK status was classified correctly, the number 
of tumor cells evaluated as ALK-positive varied tremen-
dously between the observers (even if the evaluated slides 
were closed to each other). Facultative performed IHC data 
showed heterogeneity in ALK-positive samples. This might 
be due to a lack of standardization (clone, dilution, detection 
system) for multicenter use.
In the United States, an FDA-approved ALK FISH test 
regulates the diagnostic approach whereas the European EMA 
refers to the description “ALK-positive” without stipulation of 
a certain ALK- test. Therefore, the reliability of any kind of 
ALK testing in Europe needs to be approved before therapy. 
However, based on own previous experiences,11 protein-based 
ALK detection systems provided very heterogeneous results 
due to the usage of a broad range of antibodies, dilutions and 
detection systems. As long as there is no standardized and 
harmonized immunohistochemistry, this type of ALK detec-
tion cannot be recommended for diagnostic ALK testing. 
Therefore our round robin test was based on the detection of 
genomic ALK breaks by means of FISH or CISH, as the latter 
was recently described as a reliable and suitable alternative 
option in ALK diagnostics.16,23
Nevertheless, our ALK-round robin test revealed a quite 
high failure rate of 39.7% (21 of 53) to identify ALK-positive 
cases, despite the usage of unequivocal and intensively pre-
tested cases. Due to the clearness of the cases, a successful 
participation could only be certified if 19 or 20 points (maxi-
mum 20 points) had been reached. Interestingly, the success 
rate was independent from the vendor and the type of the 
FISH probe. Furthermore even though, only two of the 32 cer-
tified institutes performed ALK testing by CISH, correct ALK 
classification does not seem to be restricted to a fluorescence-
based detection system.16,23
A further striking result was the broad range of tumor 
cells classified as ALK-break positive within one and the 
same case among the participants (Tables 2 and 3). This is 
especially interesting since only cases with high numbers of 
SS and/or SRS (41–73%) were included in our study. Case 
number 3 might serve as an example. The range of tumor 
cells evaluated as ALK-break positive by the successful 32 
participants was 15% to 95%. These observations might be 
partly explained by the minimal, however different thresh-
old used in this trial. In contrast to the cut off (≥2 spot sizes) 
within the phase III trials5,6 here obtained threshold reflects 
statistical aspects and may include “subtle splits” measur-
ing a bit less than two signal diameters (see Materials and 
Methods). This may have produced overvaluations of some 
TABLE 2.  Detailed Description of Five ALK-Break Negative Cases Indicating the Percentage of Split Signals (SS) Within 
the Prescreening, the Mean SS-Value and its Range Among the 32 Successful Participants of the Round Robin Test, and the 
Distribution of Cells Evaluated as SS (= ALK-Positive Cells) Within Each Case
Case Prescreening Result
Mean SS-Value (n = 32) 
[Range]
% Distribution of SS
0% 2–9% 10–13%
1 1% SS 4.2% [0–13%] 10/32 (31.3%) 17/32 (53.1%) 5/32 (15.6%)
2 2% SS 2.8% [0–11%] 15/32 (46.9%) 15/32 (46.9%) 2/32 (6.3%)
4 1% SS 2.8% [0–11%] 13/32 (40.6%) 18/32 (56.3%) 1/32 (3.1%)
6 1% SS 3.7% [0–12%] 12/32 (37.5%) 18/32 (56.3%) 2/32 (6.3%)
9a 3% SS 3.2% [0–13%] 13/30 (43.3%) 13/30 (43.3%) 4/30 (13.3%)
aCase 9: 2 of 32 (6.3%) participants could not evaluate this case according to technical reasons.
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tumor cells, however did not lead to false-positive results as 
the number of such subtle splits within unequivocally posi-
tive samples remains sparse. However, this cutoff discus-
sion (and therefore limitation) needs to be kept in mind for 
future QC and shows the need of standardized procedures 
within the framework of external quality assurance (EQA). 
Regardless, all ALK-break positive cases included in this QC 
displayed very prominent signal distances and clearly exceed 
the split distance of two signal diameters in the majority of 
the tumor cells (Figure 1). Independent TMA testing (per-
formed by both leading sites) showed comparable percentages 
of the ALK-break positive cells in the different TMA-levels. 
Furthermore, detailed descriptions for ALK-break positivity 
were defined in the round robin guidelines that were provided 
to all participants (for detailed explanations see Materials and 
Methods). However, comparable observations with striking 
ranges were also reported in the frame of other FISH-based 
quality rounds24 and thus might partly be explained due to 
subjectivity. This is especially true for the exact evaluations 
of a split distance diameter, directly affecting the total num-
ber of ALK-positive tumor cells. These technical aspects are 
discussed by Camidge et al.12,25,26 and McLeer-Florin et al.17,22 
describing that FISH might produce false-positive signals in 
ALK-negative tumors and in normal (non-tumor) tissue, and 
false-negative signals in ALK-positive tumors. These prob-
lems might be reinforced when alterations shall be detected 
within one chromosome as in EML4-ALK (inversion, small 
signal distance) in contrast to “real” translocations where the 
distance of the signals is wider.27–30 Despite these shortcom-
ings, FISH/CISH-based techniques are currently regarded 
as the diagnostic gold standard; however, in samples with 
an equivocal ALK FISH character (e.g. breaks between 10% 
and 20%) the reliable detection of the protein could help to 
make a clear ALK status diagnosis forming the basis for TKI 
therapy. Our recent multicenter study11 showed that protein-
based immunostainings so far tend to miss too many ALK-
positive cases. This is further underlined by the here presented 
data: Although ALK-break negative cases revealed a good 
correlation with ALK protein negativity by IHC, ALK-break 
positive cases escaped detection in many instances. The best 
IHC-result was seen in case 3 that was detected by 62.9% of 
the observers (still with a great variance concerning IHC-sore 
and percentage of positive stained tumor cells). This can be 
explained by the lack of unstandardized ALK IHC approaches 
obtained with different antibody clones, dilutions and detec-
tions systems (Supplemental Table, Supplemental Digital 
Content, http://links.lww.com/JTO/A672). To overcome this 
dilemma, efforts are under way to define reliable and validated 
standards to establish ALK IHC (for multicenter application!) 
at least as a prescreening approach followed by ALK FISH (or 
CISH?)16,23 in case of protein expression.31–36
In essence, our ALK ISH round robin test clearly dem-
onstrates that there is a need to improve the ALK testing 
quality. Although ISH may be regarded as a well-established 
procedure, its broad application in a diagnostic setting requires 
standardized methods and harmonized interpretation to 
achieve sound results for therapeutic decisions. Furthermore 
multicenter standardization of the ALK IHC approach seems TA
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inevitable. Such a validated and reliable approach could help 
the observers to express a reliable ALK diagnosis especially in 
cases that are challenging for ISH (e.g., low amounts of split 
signals between 10 and 20% or subtle splits only).
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